Fierce Pharma Mix Logo.png Fierce Pharma Mix Logo.png
Webinar

Evaluating Combinatorial Targets for Precision Therapeutics: A Pathologist’s View

ET
60 Minutes

Precision therapeutic strategies that target multiple biomarkers require a clear understanding of how those targets are expressed across patient tissues. Assessing target expression and co-expression across large tissue cohorts can help researchers evaluate the prevalence and spatial distribution of target combinations before advancing therapeutic strategies into clinical trials.

In this webinar, William Mifsud, PhD, Head of Pathology Research at Kite Pharma, shares how his pathology group uses Orion™ multiplex immunofluorescence to assess combinatorial target expression across large tissue cohorts and inform clinical trial design.

Attendees will learn:

  • How combinatorial target expression can be assessed across large tissue cohorts
  • How visual pathology review and quantitative analysis work together to characterize and quantify target co-expression
  • A live demonstration of real Orion data and the approach used to evaluate target expression patterns
  • How a small pathology team develops custom multiplex IF panels to address complex biomarker questions

Speakers

0

William Mifsud, PhD

Senior Director, Non-Clinical Safety | Head of Pathology Research
Kite Pharma, A Gilead Company

William Mifsud, PhD, is Senior Director of Non-Clinical Safety and Head of Pathology Research at Kite Pharma, a Gilead Company. He earned his PhD in developmental biology and embryology from the University of Cambridge and brings extensive experience in pathology and translational research. His published research spans pediatric and oncologic pathology, tumor biology and genomics, cell therapy, and digital and computational pathology.

0

Tad George, PhD

Senior Vice President, Biology R&D
RareCyte, Inc

Tad brings over 20 years of driving innovation at life sciences companies, building scientific markets for novel instrumentation platforms across basic research, drug discovery, and clinical applications. Prior to joining RareCyte, Tad has held similar positions at Biodesy, Inc. and DVS Sciences, and was Director of Biology at Amnis Corporation. Tad completed his B.A. in Biochemistry from the University of Texas at Austin, Ph.D. in Immunology from UT Southwestern Medical Center at Dallas, and post-doctoral training at Immunex Corp. in Seattle.

Register here!

Already registered? Click here to login.
Date/Time:
ET